Based on the charting I've seen, I think IND submission will take us to the 25 cent range. How long it stays there is another issue for this ticker as it sure seems to lack staying power with such a large OS pool.
So, what I know could take us higher than 25 cents is a partnership. Pre-IND for diabetes could also take us higher. But I think a partnership, with multi-million dollar milestone payments, would push us up and keep us there.
Positive top line data, followed by request for accelerated approval would do wonders.
Anyway, I don't have a crystal ball but I understand what CiaB could be to the right big pharma partner. Hopefully that BIO award got us the attention we deserve.
News 
Market Data 
Discover 
